Author

Ye Meng

Observed name: Ye MENG

Observed institutions: First Affiliated Hospital Zhejiang University, Zhejiang University

OpenAlex ID: A5083352437

Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed/refractory multiple myeloma

2023 · Qiqi Zhang, Cheng Zu, et al. · Frontiers in Immunology · 31

Comparable outcomes in patients with B-cell acute lymphoblastic leukemia receiving haploidentical hematopoietic stem cell transplantation: Pretransplant minimal residual disease-negative complete remission following chimeric antigen receptor T-cell therapy versus chemotherapy

2022 · Ting-Ting Yang, Ye Meng, et al. · Frontiers in Immunology · 10

Risk factors of tumor lysis syndrome in relapsed/refractory multiple myeloma patients undergoing BCMA CAR-T cell therapy

2022 · Qiqi ZHANG, Cheng ZU, et al. · Journal of Zhejiang University (Medical Sciences) · 5

Toward mechanistic endotyping in allergic rhinitis: a State–Place–Time framework for appraising nasal tissue evidence

2026 · Ye Meng, Xiang Gao · Frontiers in Immunology

Works count: 4

Citation count: 46

H-index: 3

I10-index: 2